Abstracts tagged "Transition"

Abstract Number: 1259 • 2017 ACR/ARHP Annual Meeting
Perspectives of Young People with Juvenile Idiopathic Arthritis, Their Caregivers, and Health Care Providers on Transition to Adult Care: Informing Development of a Transition Toolkit
Nadia Luca¹, Evelyn Rozenblyum², April Elliott³, Lynn R. Spiegel⁴, Nicole Johnson⁵, Sara Ahola Kohut⁶, Yvonne Brandelli³, Carolyn Johns⁷, Stephanie Luca⁸, Dianne P. Mosher⁹, Gordon Soon¹⁰, Karine Toupin-April¹¹, Gabriela Uifalusi³ and Jennifer N. Stinson¹², ¹Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ²Royal University Hospital, Saskatoon, SK, Canada, ³Alberta Children's Hospital, Calgary, AB, Canada, ⁴Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Alberta Children's Hospital, University of Calgary, Calgary, AB, Canada, ⁶Hospital for Sick Children, Toronto, ON, Canada, ⁷Alberta Health Services, Calgary, AB, Canada, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹Med, University of Calgary, Calgary, AB, Canada, ¹⁰Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ¹¹Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ¹²Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Transition from pediatric to adult care is an important process for adolescents and young adults with Juvenile Idiopathic Arthritis (JIA). A seamless transition is…
Abstract Number: 1754 • 2017 ACR/ARHP Annual Meeting
Childhood- Vs. Adult-Onset ANCA-Associated Vasculitides: A Nested, Matched Case–Control Study from the French Vasculitis Study Group Registry
Michele Iudici¹, Christian Pagnoux², Pierre Quartier³, Mathias Büchler⁴, Ramiro Cevallos⁵, Pascal Cohen⁶, Claire de Moreuil⁷, Philippe Guilpain⁸, Alain Le Quellec⁸, Jacques Serratrice⁹, Benjamin Terrier⁶, Claire Le Jeunne⁶, Loïc Guillevin¹, Luc Mouthon¹⁰ and Xavier Puéchal for the French Vasculitis Study Group¹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ²Mount Sinai Hospital, Toronto, ON, Canada, ³Necker-Enfants Malades Hospital, Paris, France, ⁴Tours, Tours, France, ⁵Strasbourg, Strasbourg, France, ⁶Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, Paris, France, ⁷CHU de Brest, Brest, France, ⁸Montpellier, Montpellier, France, ⁹Marseille, Marseille, France, ¹⁰Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France
Background/Purpose: ANCA-associated vasculitides (AAVs) are potentially life-threatening diseases rarely observed in childhood. Whether AAVs in children (cAAVs) differ from adult-onset AAVs (aAAVs) is still not…
Abstract Number: 1799 • 2017 ACR/ARHP Annual Meeting
Time to First Appointment Among Young Adults Transitioning from Pediatric to Adult Rheumatologic Care in a Safety Net Population
Nicole Bitencourt¹, Una E. Makris^1,2, Tracey Wright^3,4 and E. Blair Solow¹, ¹UT Southwestern Medical Center, Dallas, TX, ²Department of Medicine, VA North Texas Health Care System, Dallas, TX, ³Pediatrics/Rheumatology, UT Southwestern Medical Center, Dallas, TX, ⁴Texas Scottish Rite Hospital for Children, Dallas, TX
Background/Purpose: For young adults with a chronic rheumatic illness transitioning from pediatric to adult care, the transfer to new system can be daunting; these challenges…
Abstract Number: 2795 • 2017 ACR/ARHP Annual Meeting
Comparison of Switching from the Originator Rituximab to the Biosimilar Rituximab GP2013 or Re‑Treatment with the Originator Rituximab in Patients with Active Rheumatoid Arthritis: Safety and Immunogenicity Results from a Multicenter, Randomized, Double-Blind Study
Hans-Peter Tony¹, Hendrik Schulze-Koops², Klaus Krüger³, Stanley B Cohen⁴, Alan J. Kivitz⁵, Slawomir Jeka⁶, Edit Vereckei⁷, Liyi Cen⁸ and Dmitrij Kollins⁸, ¹Department of Internal Medicine 2, Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ²Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ³Praxiszentrum St. Bonifatius München, München, Germany, ⁴Metroplex Clinical Research Centre, Dallas, TX, ⁵Altoona Center for Clinical Research, Duncansville, PA, ⁶2nd University Hospital, CM UMK, Department of Rheumatology and Connective Tissue Diseases,, Bydgoszcz, Poland, ⁷National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁸Clinical Development, Sandoz, a Novartis Division, Holzkirchen, Germany
Background/Purpose: GP2013, is a biosimilar to European Union (EU) approved reference rituximab (RTX), developed in a stepwise approach that adheres to stringent biosimilar development guidelines.…
Abstract Number: 2996 • 2017 ACR/ARHP Annual Meeting
Resilience and Transition Readiness in Pediatric SLE Patients
Jamie Lai¹, Lorene Nelson², Imelda Balboni¹, Tzielan Lee¹ and Joyce Hsu¹, ¹Pediatric Rheumatology, Stanford University, Palo Alto, CA, ²Health Research and Policy - Epidemiology, Stanford University, Palo Alto, CA
Background/Purpose: Childhood onset systemic lupus erythematosus (SLE) is a chronic autoimmune condition with high morbidity that requires long-lasting care through adulthood. Transition from pediatric to…
Abstract Number: 40 • 2017 Pediatric Rheumatology Symposium
Perspectives of young people with Juvenile Idiopathic Arthritis, their caregivers, and health care providers on transition to adult care: Informing development of a transition toolkit
Nadia Luca¹, Evelyn Rozenblyum², April Elliott³, Lynn R. Spiegel⁴, Nicole Johnson⁵, Sara Ahola Kohut⁶, Yvonne Brandelli³, Carolyn Johns⁷, Stephanie Luca⁸, Dianne P. Mosher⁹, Gordon Soon¹⁰, Karine Toupin-April¹¹, Gabriela Uifalusi³ and Jennifer N. Stinson¹², ¹Pediatric Rheumatology, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ²Royal University Hospital, Saskatoon, SK, Canada, ³Alberta Children's Hospital, Calgary, AB, Canada, ⁴Rheumatology/Pediatrics, The Hospital for Sick Children, Toronto, ON, Canada, ⁵Pediatrics, University of Calgary, Alberta Children's Hospital, Calgary, AB, Canada, ⁶Hospital for Sick Children, Toronto, ON, Canada, ⁷Alberta Health Services, Calgary, AB, Canada, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹Med, University of Calgary, Calgary, AB, Canada, ¹⁰Pediatric Rheumatology, Hospital for Sick Children, Toronto, ON, Canada, ¹¹Children’s Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ¹²Anesthesia and Pain Medicine, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: A seamless transition from pediatric to adult care is critical to ensure optimal health outcomes in adolescents and young adults with Juvenile Idiopathic Arthritis…
Abstract Number: 160 • 2017 Pediatric Rheumatology Symposium
Stepping Stones to Transition Smartly
Elizabeth Roth-Wojcicki¹, Jan Lemke², Sarah Thomson³, Sarah Liedtke⁴ and Kristi Cedars², ¹Pediatrics, Medical College of WI, Wauwatosa, WI, ²Rheumatology clinic, Children's Hospital of WI, Milwaukee, WI, ³Pediatric Rheumatology, Children's Hospital of Wisconsin, Milwaukee, WI, ⁴Rheumatology clinic, Children's hospital of WI, Milwaukee, WI
Background/Purpose: Living with a rheumatic disease presents many challenges for adolescents. To help them meet these challenges and become healthy independent adults, teams need to…
Abstract Number: 126 • 2017 Pediatric Rheumatology Symposium
Challenges in Transitioning Adolescents with Rheumatologic Diseases to Adult Care – The Brazilian Experience
Ana Paula Sakamoto¹, Catherine Anelli¹, Ana Luiza Amorim¹, Fabiane Osaku², Maria Teresa Terreri¹, Claudio A. Len³ and Andreas Reiff⁴, ¹Pediatric Rheumatology Unit, Federal University of São Paulo (UNIFESP - Universidade Federal de São Paulo), São Paulo, Brazil, ²Pediatric Rheumatology, Federal University of São Paulo (UNIFESP - Universidade Federal de São Paulo), São Paulo, Brazil, ³Pediatric Rheumatology Unit, Federal University of São Paulo (UNIFESP - Universidade Federal de São Paulo), São Paulo,, Brazil, ⁴Division of Rheumatology MS 60, Children’s Hospital Los Angeles, Keck School of Medicine, University of Southern California, USA, Los Angeles, CA
Background/Purpose: Due to the high survival rates in chronic pediatric rheumatologic diseases a well-structured and effective transition process becomes crucial to guarantee continuity of care…
Abstract Number: 3113 • 2016 ACR/ARHP Annual Meeting
Evaluation of a Clinical Transition Pathway for Adolescents with Autoimmune Diseases
Margot Walter¹, Sylvia S.M. Kamphuis^2,3, Philomine A. van Pelt⁴, A. Vroed de⁵ and Johanna M.W. Hazes⁶, ¹Rheumatology, Erasmus MC - University Medical Center, Rotterdam, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands, ³Pediatric Rheumatology, Sophia Children's Hospital – Erasmus University Medical Centre, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus MC, Rotterdam, Netherlands, ⁵ErasmusMC, Rotterdam, Netherlands, ⁶Department of Rheumatology, Erasmus University Medical Centre, Rotterdam, Netherlands
Background/Purpose: It is clear that young people (YP) with an autoimmune disease need a transitional process before they are transferred to the adult clinic. Therefore,…
Abstract Number: 1399 • 2016 ACR/ARHP Annual Meeting
Transitioning Lupus Patients from Pediatric to Adult Rheumatology
Joyce Hui-Yuen¹, Ashlea Cook², Lisa F. Imundo³, Amy Starr², Andrew Eichenfield⁴ and Anca D. Askanase⁵, ¹North Shore-Long Island Jewish Health System, Lake Success, NY, ²Pediatric Rheumatology, Columbia University Medical Center, New York, NY, ³Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY, ⁴Morgan Stanley Children's Hospital of NY-Presbyterian, Columbia University, New York, NY, ⁵Department of Medicine, Rheumatology, Columbia University College of Physicians & Surgeons, New York, NY
Background/Purpose: Pediatric rheumatologists have successfully improved the life expectancy and quality of life of children with systemic lupus (cSLE). cSLE has higher morbidity and mortality…
Abstract Number: 400 • 2015 ACR/ARHP Annual Meeting
Disease Activity and Health Care Utilization Among Young Adults with Childhood-Onset Lupus Transitioning to Adult Care: Data from the Pediatric Lupus Outcomes Study
Erica F. Lawson¹ and Aimee O. Hersh², ¹Pediatrics/Rheumatology, UC San Francisco, San Francisco, CA, ²Pediatrics/Rheumatology, University of Utah, Salt Lake City, UT
Background/Purpose: Individuals with childhood-onset systemic lupus erythematosus (cSLE) must transfer from pediatric- to adult-oriented health care as they enter adulthood. However, few studies have assessed…
Abstract Number: 1466 • 2015 ACR/ARHP Annual Meeting
Assessment of Transition Readiness in Adolescents and Young Adults with Chronic Health Conditions
Paul Jensen^1,2, Gabrielle Paul³, Stephanie LaCount⁴, Brendan Boyle⁵, Manmohan K. Kamboj⁶ and Stacy P. Ardoin⁷, ¹Rheumatology, Nationwide Children's Hospital, Columbus, OH, ²Medicine, Ohio State University Medical Center, Columbus, OH, ³College of Medicine, Ohio State University, Columbus, OH, ⁴Pediatrics, Nationwide Children's Hospital, Columbus, OH, ⁵Gastroenterology, Nationwide Children's Hospital, Columbus, OH, ⁶Endocrinology, Nationwide Children's Hospital, Columbus, OH, ⁷Pediatric & Adult Rheumatology, Ohio State University, Columbus, OH
Background/Purpose: The transition from pediatric to adult care is a vulnerable period associated with increased morbidity and mortality. Guidelines call for assessing patients’ transition readiness…
Abstract Number: 1675 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Switched CT-P10 from Innovator Rituximab Compared to Those of Maintained CT-P10 in Patients with Rheumatoid Arthritis up to 56 Weeks
Dae-Hyun Yoo¹, Won Park², Chang-Hee Suh³, Seung-Cheol Shim⁴, Fidencio Cons Molina⁵, Slawomir Jeka⁶, Jan Brzezicki⁷, Francisco G. Medina-Rodriguez⁸, Pawel Hrycaj⁹, Piotr Wiland¹⁰, Eun Young Lee¹¹, Pavel Shesternya¹², Volodymyr Kovalenko¹³, Leysan Myasoutova¹⁴, Marina Stanislav¹⁵, Sebastiao Radominski¹⁶, Mie Jin Lim¹⁷, Jung-Yoon Choe¹⁸, Sung Young Lee¹⁹ and Sang Joon Lee²⁰, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Inha University Hospital, Incheon, South Korea, ³Department of Rheumatology, Ajou University Hospital, Suwon, South Korea, ⁴Department of Internal Medicine, Chungnam National University Hospital, Daejeon, South Korea, ⁵Centro de Investigacion en Artritis y Osteoporosis, Mexicali, Mexico, ⁶University Hospital Nr 2 Dr. Jan Biziel, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Clinic of Rheumatology and Connective Tissue Diseases, Bydgoszcz, Poland, ⁷Wojewodzki Szpital Zespolony w Elablagu, Elblag, Poland, ⁸Rheumatology, LaSalle University, Mexico City, Mexico, ⁹Department of Rheumatology and Clinical Immunology, Poznan University of Medical Sciences, Poznan, Poland, ¹⁰Department of Rheumatology, Medical University of Wroclaw, Wroclaw, Poland, ¹¹Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ¹²Rheumatology Department, Krasnoyarsk State Medical University, Krasnoyarsk, Russia, ¹³Section of Non-coronarogenic Myocardial Diseases and Clinical Rheumatology, National Scientific Center, Kiev, Ukraine, ¹⁴City Reumatology Center, Research Medical Complex Vashe Zdorovie, Kazan, Russia, ¹⁵Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia, ¹⁶CETI-Centro de estudos em Terapias Inovadoras, Universidade Federal do Parana, Curitiba, Brazil, ¹⁷Division of Rheumatology, Departments of Internal Medicine, Inha University Hospital, Incheion, South Korea, ¹⁸Internal Medicine, Catholic University of Daegu, School of Medicine, Daegu, South Korea, ¹⁹Clinical Planning Department, CELLTRION, Inc., Incheon, South Korea, ²⁰CELLTRION, Inc., Incheon, South Korea
Background/Purpose: Pharmacokinetic (PK) equivalence and similarity of clinical efficacy, safety and immunogenicity up to week 24 were demonstrated between CT-P10, a biosimilar candidate for innovator…
Abstract Number: 2902 • 2014 ACR/ARHP Annual Meeting
The Health Status of Patients with Juvenile Idiopathic Arthritis (JIA) Significantly Worsens after Transfer from Pediatric to Adult Care
Kirsten Minden¹, Jens Klotsche², Martina Niewerth², Angela Zink³ and Gerd Horneff⁴, ¹Chidlrens´ hospital, Charité University Medicine, Berlin, Germany, ²Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ³German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany
Background/Purpose A minority of patients with polyarticular JIA enter adulthood in drug free remission. Thus, patients are in need of care beyond adolescence. There is…
Abstract Number: 1604 • 2014 ACR/ARHP Annual Meeting
IFN-γ (Th₁), IL4 (Th₂), and IL5 (Th₂) Are Elevated in Pre-Clinical SLE and Predict Transition to Classified Disease Prior to Appearance of Autoantibodies or Clinical Criteria
Rufei Lu^1,2, Melissa E. Munroe³, Joel M. Guthridge², Krista M. Bean², Dustin Fife², John B. Harley⁴, Judith A. James⁵ and Michael P. Keith⁶, ¹Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Rheumatology, Walter Reed National Military Medical Center, Bethesda, MD
Background/Purpose Systemic Lupus Erythematosus (SLE) is a clinically diverse autoimmune disease that often begins with a pre-disease period of autoantibody production and symptom accrual.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].